IMGN529: Phase I data

Data from 22 evaluable patients in an open-label, dose-escalation, U.S. and Swiss Phase I trial showed that 0.1-0.8 mg/kg IV IMGN529 on day 1 of each 21-day cycle led to 2 partial remissions. DLTs con...